HLX05 (cetuximab biosimilar) / Fosun Pharma, Jingze Biotech - LARVOL DELTA

Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics (clinicaltrials.gov) - P1 | N=322 | Active, not recruiting | Sponsor: Shanghai Henlius Biotech | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Oncology

Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics (clinicaltrials.gov) - P1 | N=322 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

New P1 trial • Oncology

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects (clinicaltrials.gov) - P1 | N=268 | Active, not recruiting | Sponsor: Shanghai Henlius Biotech | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Enrollment closed • Trial completion date • Trial primary completion date

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects (clinicaltrials.gov) - P1 | N=268 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

New P1 trial